Trial Profile
A Study to Compare the Overall Survival and Hospitalization Rates Between Medicare Patients With Advanced Non Small Cell Lung Cancer (NSCLC) Treated With Bevacizumab-Carboplatin-Paclitaxel and Carboplatin-Paclitaxel
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 26 Dec 2015
Price :
$35
*
At a glance
- Drugs Bevacizumab (Primary) ; Carboplatin (Primary) ; Paclitaxel (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 26 Dec 2015 New trial record